Dohj LLC Takes $377,000 Position in Danaher Co. (NYSE:DHR)

Dohj LLC purchased a new position in shares of Danaher Co. (NYSE:DHR) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 1,630 shares of the conglomerate’s stock, valued at approximately $377,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GHP Investment Advisors Inc. boosted its position in Danaher by 540.0% during the third quarter. GHP Investment Advisors Inc. now owns 160 shares of the conglomerate’s stock worth $40,000 after purchasing an additional 135 shares during the period. Koshinski Asset Management Inc. raised its stake in shares of Danaher by 16.2% during the 3rd quarter. Koshinski Asset Management Inc. now owns 1,118 shares of the conglomerate’s stock valued at $277,000 after purchasing an additional 156 shares during the period. Town & Country Bank & Trust CO dba First Bankers Trust CO lifted its holdings in Danaher by 0.4% during the 3rd quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO now owns 12,904 shares of the conglomerate’s stock worth $3,201,000 after purchasing an additional 54 shares in the last quarter. Walkner Condon Financial Advisors LLC boosted its stake in Danaher by 6.6% in the 3rd quarter. Walkner Condon Financial Advisors LLC now owns 906 shares of the conglomerate’s stock worth $225,000 after purchasing an additional 56 shares during the period. Finally, Valeo Financial Advisors LLC grew its holdings in Danaher by 20.1% during the 3rd quarter. Valeo Financial Advisors LLC now owns 12,396 shares of the conglomerate’s stock valued at $3,075,000 after buying an additional 2,076 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 0.3 %

Danaher stock traded up $0.78 during trading hours on Friday, reaching $246.58. The company had a trading volume of 2,710,446 shares, compared to its average volume of 2,710,897. The firm has a market cap of $182.64 billion, a price-to-earnings ratio of 41.77, a P/E/G ratio of 3.78 and a beta of 0.83. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $259.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.37. The company has a 50-day moving average price of $248.87 and a 200 day moving average price of $231.08.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The firm’s revenue was down 2.6% compared to the same quarter last year. During the same period in the prior year, the business posted $2.36 EPS. Equities analysts forecast that Danaher Co. will post 7.65 earnings per share for the current year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, April 26th. Investors of record on Thursday, March 28th were paid a $0.27 dividend. The ex-dividend date was Wednesday, March 27th. This is a boost from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Activity

In other news, SVP Daniel Raskas sold 23,757 shares of the firm’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the sale, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, SVP Brian W. Ellis sold 4,000 shares of the company’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total value of $1,000,040.00. Following the sale, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at approximately $7,457,798.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the transaction, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at $9,601,704. The disclosure for this sale can be found here. Over the last three months, insiders have sold 106,565 shares of company stock valued at $26,641,364. Company insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

DHR has been the subject of several analyst reports. Raymond James boosted their price target on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Royal Bank of Canada raised their target price on shares of Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. KeyCorp boosted their price target on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Finally, Citigroup lifted their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday. Six investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $270.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.